Literature DB >> 30989487

Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.

Kota Yoshifuji1, Takashi Toya2, Hiroto Adachi1, Masahiro Fujita1, Atsushi Wada1, Ryosuke Konuma1, Yuya Kishida1, Tatsuya Konishi1, Akihito Nagata1, Yuta Yamada1, Satoshi Kaito1, Takuma Kumagai1, Kyoko Inamoto1, Megumi Akiyama1, Aiko Igarashi1, Yuho Najima1, Noriko Doki1, Takeshi Kobayashi1, Kazuhiko Kakihana1, Hisashi Sakamaki1, Kazuteru Ohashi1.   

Abstract

Autologous stem-cell transplantation is an effective procedure for the treatment of multiple myeloma, and involves the collection of hematopoietic stem cells (HSCs). However, in some patients, HSCs in the bone marrow fail to mobilize. Pomalidomide upregulates CXCR4 in hematopoietic stem cells, in a manner similar to that of lenalidomide, and is, thus, likely to have a negative impact on hematopoietic stem-cell mobilization in multiple myeloma patients. Here, we report the two cases in which hematopoietic stem cells were mobilized using plerixafor plus granulocyte-colony stimulating factor after exposure to lenalidomide and pomalidomide. Use of plerixafor with a sufficient washout period may lead to successful mobilization following pomalidomide use, although further study of this potential use is needed.

Entities:  

Keywords:  CXCR4; Multiple myeloma; Plerixafor; Pomalidomide; Stem-cell mobilization

Mesh：

Substances：

Year:  2019        PMID： 30989487     DOI： 10.1007/s12185-019-02622-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  19 in total

1.  Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.

Authors:  H Paripati; A K Stewart; S Cabou; A Dueck; V J Zepeda; N Pirooz; C Ehlenbeck; C Reeder; J Slack; J F Leis; J Boesiger; A S Torloni; R Fonseca; P L Bergsagel
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

2.  Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.

Authors:  I N M Micallef; A D Ho; L M Klein; S Marulkar; P J Gandhi; G Calandra; P A McSweeney
Journal:  Bone Marrow Transplant       Date:  2010-05-17       Impact factor: 5.483

3.  Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization.

Authors:  S Li; J Fu; H Ma; M Y Mapara; S Lentzsch
Journal:  Leukemia       Date:  2012-11-09       Impact factor: 11.528

4.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

5.  The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

Authors:  Neal Flomenberg; Steven M Devine; John F Dipersio; Jane L Liesveld; John M McCarty; Scott D Rowley; David H Vesole; Karin Badel; Gary Calandra
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

6.  Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.

Authors:  Nigel Russell; Kenny Douglas; Anthony D Ho; Mohamad Mohty; Kristina Carlson; G J Ossenkoppele; Giuseppe Milone; Macarena Ortiz Pareja; Daniel Shaheen; Arnold Willemsen; Nicky Whitaker; Christian Chabannon
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

7.  Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.

Authors:  Tomer Mark; Jessica Stern; Jessica R Furst; David Jayabalan; Faiza Zafar; April LaRow; Roger N Pearse; John Harpel; Tsiporah Shore; Michael W Schuster; John P Leonard; Paul J Christos; Morton Coleman; Ruben Niesvizky
Journal:  Biol Blood Marrow Transplant       Date:  2008-07       Impact factor: 5.742

8.  Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.

Authors:  S Kumar; A Dispenzieri; M Q Lacy; S R Hayman; F K Buadi; D A Gastineau; M R Litzow; R Fonseca; V Roy; S V Rajkumar; M A Gertz
Journal:  Leukemia       Date:  2007-06-21       Impact factor: 11.528

Review 9.  Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.

Authors:  Sergio Giralt; Luciano Costa; Jeffrey Schriber; John Dipersio; Richard Maziarz; John McCarty; Paul Shaughnessy; Edward Snyder; William Bensinger; Edward Copelan; Chitra Hosing; Robert Negrin; Finn Bo Petersen; Damiano Rondelli; Robert Soiffer; Helen Leather; Amy Pazzalia; Steven Devine
Journal:  Biol Blood Marrow Transplant       Date:  2013-10-17       Impact factor: 5.742

10.  Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.

Authors:  I Sánchez-Ortega; S Querol; M Encuentra; S Ortega; A Serra; J M Sanchez-Villegas; J R Grifols; M M Pujol-Balaguer; M Pujol-Bosch; J M Martí; T Garcia-Cerecedo; P Barba; J M Sancho; A Esquirol; J Sierra; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-09-15       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.